Last reviewed · How we verify
GH treatment (Genotropin)
Genotropin is recombinant human growth hormone (somatropin) that binds to growth hormone receptors to stimulate growth, metabolism, and body composition changes.
Genotropin is recombinant human growth hormone (somatropin) that binds to growth hormone receptors to stimulate growth, metabolism, and body composition changes. Used for Growth hormone deficiency in children, Growth hormone deficiency in adults, Short stature due to Turner syndrome.
At a glance
| Generic name | GH treatment (Genotropin) |
|---|---|
| Sponsor | Rabin Medical Center |
| Drug class | Recombinant human growth hormone (somatropin) |
| Target | Growth hormone receptor (GHR) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Genotropin mimics endogenous growth hormone by activating GH receptors on target tissues, promoting linear growth in children, increasing lean body mass, reducing fat mass, and enhancing metabolic function. It stimulates insulin-like growth factor 1 (IGF-1) production, which mediates many of growth hormone's anabolic effects.
Approved indications
- Growth hormone deficiency in children
- Growth hormone deficiency in adults
- Short stature due to Turner syndrome
- Chronic kidney disease-related growth failure
- Prader-Willi syndrome
Common side effects
- Injection site reactions
- Headache
- Hyperglycemia
- Fluid retention
- Carpal tunnel syndrome
- Arthralgia
Key clinical trials
- Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency (PHASE3)
- Effects of Recombinant Human Growth Hormone in Elderly Patients With Moderate to Severe Acute Brain Injury (GH-ABI-RCT) (PHASE4)
- Growth Hormone Administration and the Human Immune System (PHASE1)
- Effects of GH and Lirglutide on AgRP (PHASE4)
- Effects of Ketone Bodies on Insulin Sensitivity (NA)
- Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency (PHASE2)
- Study of the Efficacy and Safety of Somatropin in Japanese Participants With PWS (PHASE3)
- Growth Hormone in Decompensated Liver Cirrhosis (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GH treatment (Genotropin) CI brief — competitive landscape report
- GH treatment (Genotropin) updates RSS · CI watch RSS
- Rabin Medical Center portfolio CI